Ipilimumab in the treatment of metastatic melanoma: management of adverse events
Della Vittoria Scarpati, Giuseppina
MetadataShow full item record
CitationDella Vittoria Scarpati, Giuseppina, Celeste Fusciello, Francesco Perri, Francesco Sabbatino, Soldano Ferrone, Chiara Carlomagno, and Stefano Pepe. 2014. “Ipilimumab in the treatment of metastatic melanoma: management of adverse events.” OncoTargets and therapy 7 (1): 203-209. doi:10.2147/OTT.S57335. http://dx.doi.org/10.2147/OTT.S57335.
AbstractRecently, “ipilimumab,” an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody, has been demonstrated to improve overall survival in metastatic melanoma. “CTLA-4” is an immune-checkpoint molecule that downregulates pathways of T-cell activation. Ipilimumab, by targeting CTLA-4, is able to remove the CTLA-4 inhibitory signal, allowing the immune system to react to cancer cells. Due to its immune-based mechanism of action, ipilimumab causes the inhibition of CTLA-4-mediated immunomodulatory effects, the enhancement of antitumor specific immune response mediated by the weakening of self-tolerance mechanisms while exacerbating the development of autoimmune diseases and immune-related adverse events, including dermatitis, hepatitis, enterocolitis, hypophysitis, and uveitis.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11879891
- HMS Scholarly Articles